News for Moderna, Inc. (MRNA.MX)

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.65%, j

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Moderna (MRNA) experienced a notable upswing in its stock price, climbing by $1.29 or 3.95%, to approximately $34.09. The trading session revealed reduced optio

Key Takeaways: The FDA approval expands Moderna's Spikevax usage to children over six months old. Analysts predict a significant price movement for Moder

Shares of Moderna (MRNA) experienced a modest rise, gaining $0.29, or 0.89%, reaching approximately $32.83. The stock saw a significant surge in options trading

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.41%, j

Key Takeaways: Moderna (MRNA) experiences notable growth, with its stock price surging by 10.71% amid strong performance in the S&P 500 Health Care Index.

Key Highlights: FDA restricts Moderna's COVID-19 vaccine use, impacting target demographics. Wall Street analysts show a mixed outlook with varied price

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Shares of Moderna (MRNA) saw a rise of 71 cents, or 2.64%, reaching approximately $27.57. This price movement coincided with a significant surge in options trad

Shares of Moderna (MRNA) have experienced a slight uptick, rising by $0.22 or 0.88%, to approximately $25.77. The stock saw a significant surge in options tradi

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:MRNA) and AbbVie (NYSE:ABBV), according to its prospectu

Shares of Moderna (MRNA) saw a slight dip, falling 20 cents to approximately $25.80 amid a bearish outlook from option traders. The trading activity was relativ

Moderna, Inc. (NASDAQ:MRNA) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ETCompany ParticipantsStéphane Bancel - CEO &...

Moderna Inc. (MRNA) experienced a minor dip in its stock price, falling by 22 cents to approximately $27.92. Despite the decline, the options trading atmosphere

(Bloomberg) -- This year’s stock market turbulence has punished ordinary investors. But for the wealthy, it’s opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. Most Read from BloombergTrump Said He Fired the National Portrait Gallery Director. She’s Still There.NYC Mayoral Candidates All Agree on Building More Housing. But Where?Senator Calls for Closing Troubled ICE Detention Facility

Moderna, Inc. (NASDAQ:MRNA) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ETCompany ParticipantsStephen Hoge - PresidentConference Call...

Long-established in the Biotechnology industry, Moderna Inc (MRNA) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 1.26%, j

Moderna's new placebo-controlled trial aims to expand its recently approved mNEXSPIKE vaccine. Analysts project a significant 68.46% upside potential fo